셀레스트라

352770KOSDAQView the 제약 sectorTheme Bio & healthcare

5,250KRWMarket close of 10/20 (Tue)

No trade that dayMarket close of 10/20 (Tue)

Preliminary value right after the close — replaced by official KRX data tomorrow morningClose of 10/21 (Wed)5,250KRWFlat 0.00%

Preliminary · just after the close · replaced by official KRX data tomorrow morning

Volume: 0×10K shares
: 0 KRW

Open, high and low are not shown — the source has no bar for the reference date

Market close of 10/20 (Tue)

Where it sits in the 1-year range

4% of the way up from the lowest close in 1 year (252 sessions) · -83.4% from the high

Something to check

2 to check: no trades this day · operating loss

Free · no sign-inSource from 2021-05-17

Points to check

Daily moveto checkNo trades this day (0 shares)
Earningsto check-5.1B KRWOperating income over the last four quarters -5.1B KRW (loss)Operating income, 8 quarters
Trading valuenot verifiedNo trading that day, so not compared with usual trading value

The other 3

Recent filingsnot verified
Foreign & institutionalnot verified
Data date10/20 (Tue)Market close

See the full check report

Key figures

: 13.6B KRW
: Not computed — loss-making, or the four quarters are incomplete
: Not computed — loss-making, or the four quarters are incomplete
: 2,592,407 shares

52-week closing rangeNow 5,250

2852,110

Financials filed 2026-05-15 · KRX·DART

Something to check

2 to check: no trades this day · operating loss

Daily moveto checkNo trades this day (0 shares)
Earningsto checkQuarterly operating income bars (6); the four dark bars make up the sum-5.1B KRW
Trading valuenot verifiedNo trading that day, so not compared with usual trading value
Recent filingsnot verifiedOutside filing data coverage, so not verified
Foreign & institutionalnot verifiedOutside investor-flow coverage, so not verified
Data dateusual rangeMarket close data of 2026-10-20

Quarterly results · Q1 2026

Source: DART financials (Q4 derived as annual − three quarters) · Amended filing reflected

Revenue24.09 million KRWRevenue bars for the last 8 quarters; the dark bar is this quarter
vs. year ago
-95.7%
vs. prior quarter
Turned profitable
Operating income-253.54 million KRWOperating income bars for the last 8 quarters; the dark bar is this quarter
vs. year ago
Still a loss
vs. prior quarter
Still a loss
Operating margin-1,052.6%Operating margin bars for the last 8 quarters; the dark bar is this quarter
vs. year ago
-542.9 pp
vs. prior quarter
—

Quarterly operating income trend

As of the latest official close · 2026-10-20Valuation filing date · 2026-05-15

2021Q1 -1.1B KRW2026Q1 -253.54 million KRWQ4 values are derived as the annual figure minus Q1–Q3. The value table marks them in the Type column.

Same sector · 제약

· 29 of 168 stocks up, preferred shares excluded · trading value 827.8B KRW

Same sector · top by trading value
Stock	20D	Change	Trading value
셀트리온	Close over the last 20 sessions +11.4%	Down -0.40%	139.2B KRW
삼성바이오로직스	Close over the last 20 sessions -1.3%	Down -2.52%	129.9B KRW
삼익제약	Close over the last 20 sessions -20.4%	Up +2.77%	76.0B KRW
녹십자엠에스	Close over the last 20 sessions +30.5%	Up +6.67%	55.6B KRW
유한양행	Close over the last 20 sessions +11.5%	Down -1.37%	41.6B KRW

Schedule

Next data 10/22 (Thu) after 08:50

Investor flows, financials and valuation are provided for 369 stocks. These stocks account for about 81% of trading value, about 92% of market capitalisation. Coverage status →

For information only, not a solicitation to invest. Investment decisions and their results are your own responsibility.